The FDA has issued a black box warning for<unk>  for embryo-fetal toxicity. It is only available to females in the U.S through a risk evaluation and mitigation strategy (REMS) program.
Macitentan
Bosentan
Sitaxentan
Ambrisentan
Darusentan
Sildenafil
Telmisartan
Vericiguat